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Recently, twomulticenter reports in theMay and June issues
of Biology of Blood and Marrow Transplantation showed that
peripheral blood stem cells (PBSCs) can be used safely and
effectively as the graft source for transplantation from hap-
loidentical donors after reduced-intensity conditioning for
treatment of high-risk hematologic malignancies [1,2]. Both re-
ports used post-transplant cyclophosphamide (PTCy) to elimi-
nate alloreactive T cells as previously described [3]. Our own
publication [2] was a 4-center study of 55 patients with acute
leukemiasor lymphomaswitha17-monthmedian follow-up.Of
note, a preliminary report of our ﬁrst 29 patients was reported
in abstract form at the Tandem BMTMeetings of 2012 [4].
In the setting of haploidentical transplantation of PBSCs
after an ablative conditioning regimen and use of PTCy as
graft-versus-host disease (GVHD) prophylaxis, Solomon et al.
[5] and Grosso et al. [6] reported that high fever was
commonly observed at 4 to 5 days post-transplant. In the
absenceof documented infection, itwashypothesized that the
feverwas likely a cytokine-mediated phenomenon associated
either with initial proliferation of alloreactive T cells or from
the actual destruction of alloreactive T cells by PTCy given per
protocol on days þ3 and þ4. Here, we report that a similar
incidence of high fever at 4 to 5 days post-transplant also was
observed in our recently reported study of haploidentical
PBSCs [2]. A similar ﬁnding of high fever post-transplant also
was observed in patients who had undergone bone marrow
transplantation from haploidentical donors [7]. The median
Tmax of patients transplanted with PBSCs (39.7C) was signif-
icantly higher than the Tmax of patients transplanted with
bone marrow (38.6C, P ¼ .007), possibly reﬂecting the 5- to
10-fold greater content of T cells in PBSC allografts fromFinancial disclosure: See Acknowledgments on page 197.
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hemodynamic instability was not observed in any patient. It
does not appear that the high fevers were associated strictly
with use of PTCy as GVHD prophylaxis because high fevers
were not observed (median T max of 37C) in a sample of 10
patients who had undergone bone marrow transplantation
from HLA-matched related or unrelated donors after
conditioning with a busulfaneﬂudarabine conditioning
regimen and use of PTCy as the only GVHD prophylaxis [8].
As more centers begin to use the novel approach of PTCy
as GVHD prophylaxis, physicians should be aware that high
fevers early post-transplant are a common feature after
transplantation of haploidentical bone marrow or PBSCs
regardless of conditioning intensity but not after trans-
plantation of bone marrow fromHLA-matched donors. Fever
usually resolves spontaneously by post-transplant days þ5
to þ6 and does not require treatment with glucocorticoids.
Although the fevers at post-transplant days þ4 toþ5 may be
predominantly noninfectious, patients may be neutropenic
secondary to the myelosuppressive effect of agents used in
different conditioning regimens and so are likely be treated
empirically for infection in any event.
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In a recent issue of this journal, Yanez et al. [1] reported an
unexpected outbreak of Epstein-Barr virus (EBV) post-
transplantation lymphoproliferative disorder (PTLD) after
allogeneic hematopoietic stem cell transplantation (allo-
HSCT) conditioning with Thymoglobulin (Genzyme-Sanoﬁ,
Lyon, France). Although we agree with the authors’ conclu-
sion that antithymocyte globulin is a complex biological
agent with broad immune effects [2] and some yet unre-
solved questions, such as the best regimen, schedule, and
dose, we believe that their observation about a so-called
unexpected outbreak of EBV PTLD is weak and their claims
are not substantiated by the little data presented.
EBV PTLD is a serious complication that usually occurs in a
state of profound immunosuppression. After allo-HSCT, EBV
reactivation and EBV-related proliferations are well-
recognized complications. EBV reactivation may be associ-
ated with a spectrum of clinical presentations, from fever to
lymphoproliferative disease, which arise as a consequence of
an outgrowth of B cells latently infected with EBV in the
setting of loss or suppression of normal cytotoxic T cell sur-
veillance. Risk factors for EBV-related complications include
manipulation of the graft to deplete T cells, degree and
duration of immunosuppression used to prevent and treat
graft-versus-host disease, and degree of mismatch between
donor and recipient [3]. Interestingly, Yanez et al. [1]
acknowledged in their series a higher percentage of patients
who underwent transplantation with a mismatched donor,
which is a major risk factor for graft-versus-host disease and
its corollary of multiple lines of immunosuppressive agents
[4]. Indeed, patients who develop EBV PTLD are usually
severely immunosuppressed while receiving high-dose
corticosteroid therapy at time of EBV PTLD occurrence.
At present, it is also well established that regular and
close DNA-PCR screening for EBV reactivation is mandatoryafter allo-HSCT, and preemptive treatment with rituximab
should be started as soon as the EBV DNA level exceeds the
standard institutional threshold. With such a strategy of
preemptive treatment of EBV reactivation, the incidence of
EBV PTLD can be signiﬁcantly reduced [3]. From the report by
Yanez et al., it appears that this group does not routinely use
such a preemptive approach.
Finally, from a methodological standpoint, the interpre-
tation of Yanez et al.’s observation [1] deserves some caution.
In fact, for determining whether a parameter is causally
related to a given disease or complication, scientists have
established some rigorous guidelines [5]. According to Hill’s
criteria, evidence for causality depends on (1) strength of
association, (2) speciﬁcity, (3) temporality, (4) consistency/
reproducibility, (5) biologic gradient, (6) biologic plausibility,
and (7) experimental evidence [5]. Unfortunately, the obser-
vation by Yanez et al. [1] does not fulﬁll most of these criteria.
In the 30 years since the rabbit antithymocyte globulin,
Thymoglobulin (Genzyme-Sanoﬁ), as ﬁrst licensed, its use in
solid organ transplantation and hematology continues to in-
crease signiﬁcantly worldwide. Over time, clinicians have
learned how to better balance the beneﬁts and risks associated
with this product. Thus, despite its longhistory, Thymoglobulin
(Genzyme-Sanoﬁ) will remain a key component of the immu-
nosuppressive armamentarium in theallo-HSCTsetting, and its
complex immunological properties indicate that its use will
continue to expand to awider rangeofdisease conditions in the
future.
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